Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
DMTF1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9Y222 |
|---|---|
| Clone Names | 100712185 |
| Gene ID | 9988 |
|---|---|
| Other Names | Cyclin-D-binding Myb-like transcription factor 1, hDMTF1, Cyclin-D-interacting Myb-like protein 1, hDMP1, DMTF1, DMP1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | DMTF1 |
|---|---|
| Synonyms | DMP1 |
| Function | Transcriptional activator which activates the CDKN2A/ARF locus in response to Ras-Raf signaling, thereby promoting p53/TP53- dependent growth arrest (By similarity). Binds to the consensus sequence 5'-CCCG[GT]ATGT-3' (By similarity). Isoform 1 may cooperate with MYB to activate transcription of the ANPEP gene. Isoform 2 may antagonize transcriptional activation by isoform 1. |
| Cellular Location | Nucleus {ECO:0000255|PROSITE-ProRule:PRU00625, ECO:0000269|PubMed:17936562} |
| Tissue Location | Expressed at relatively low levels in colonic mucosa, ovary, peripheral leukocytes, prostate and small intestine, and at higher levels in spleen, testis and thymus. Expressed in multiple regions of the brain and CNS including amygdala, caudate, corpus callosum, hippocampus, substantia nigra and subthalamic nucleus Isoform 1 is the predominant isoform in monocytes, macrophages and neutrophils, isoform 2 is most strongly expressed in peripheral blood leukocytes and quiescent CD34 positive cells, and isoform 3 is expressed at low levels in all hematopoietic cell types. Expression is frequently reduced in non-small-cell lung carcinomas (NSCLC) due to hemizygous gene deletion, strongly suggesting that this locus is haploinsufficient for tumor suppression. Loss of this locus frequently occurs in tumors which retain wild-type CDKN2A/ARF and p53/TP53 loci Hemizygous gene deletion has also been observed in leukemic blasts from patients with abnormalities of the long arm of chromosome 7 |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a transcription factor that contains acyclin D-binding domain, three central Myb-like repeats, and twoflanking acidic transactivation domains at the N- and C-termini.The encoded protein is induced by the oncogenic Ras signalingpathway and functions as a tumor suppressor by activating thetranscription of ARF and thus the ARF-p53 pathway to arrest cellgrowth or induce apoptosis. It also activates the transcription ofaminopeptidase N and may play a role in hematopoietic celldifferentiation. The transcriptional activity of this protein isregulated by binding of D-cyclins. This gene is hemizygouslydeleted in approximately 40% of human non-small-cell lung cancerand is a potential prognostic and gene-therapy target fornon-small-cell lung cancer. Multiple transcript variants encodingdifferent isoforms have been found for this gene. [provided byRefSeq].
References
Liu, Y., et al. Mol. Psychiatry (2010) In press :Sugiyama, T., et al. Expert Rev. Mol. Diagn. 8(4):435-447(2008)Inoue, K., et al. Cancer Res. 68(12):4487-4490(2008)Tschan, M.P., et al. Leukemia 22(5):1087-1090(2008)Mallakin, A., et al. Cancer Cell 12(4):381-394(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
